were undergoing topical medical treatment to both eyes.
Seven patients were on timolol 0.5% twice a day; 6 patients applied pilocarpine 4% four times a day; and the remaining 6 patients underwent treatment with both timolol 0.5% twice a day and pilocarpine 4% four times a day. Subjects were informed about the nature of the study and consent was obtained before the withdrawal of 5 ml of blood from the antecubital vein with a 21 gauge catheter. All blood samples were stored in heparin tubes until the time of testing.
In vitro study
To assess the effect of antiglaucomatous therapy in our findings, we studied 26 non-glaucomatous patients attending the eye clinic: 14 men and 12 women, age range 40-71 years. None suffered from high blood pressure, anaemia, diabetes, diseases of the central nervous system or any other disease known to affect AChE activity. s They were not undergoing any form of treatment, either topical or systemic, at the time of the study, and those who smoked were asked to refrain from smoking for 48 h before withdrawal of the blood sample.
We carried out an in vitro study in which patients' blood samples (8 ml) were divided into four aliquots of 2 ml each. One of the aliquots served as a control; 
Results
In the ex vivo study we verified a significant increase in RBC AChE activity ( (Fig. 1 ).
In the in vitro study, pilocarpine lO-s M significantly decreased RBC AChE enzyme activity (247 ± 36; P = 0.008), as did timolol maleate lO-s M (264 ± 37.6; P = 0.05) ( Table 3 ). The reducing effect was greater when the two drugs acted simultaneously (245 ± 45.1; p = 0.002) (Fig. 2) . We are grateful to Dr L. Sargento and Mrs T. Freitas for their support.
